
    
      Evaluation of the effectiveness of ClobexÂ® Spray, 0.05% when used as monotherapy or add-on
      therapy to existing systemic or topical anti-psoriatic agents, as determined by the change in
      the target plaque severity (TPS) rating between Weeks 0 and 4.
    
  